Clinical Trials
56 trialsBenmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeĀ±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
Henan Cancer Hospital
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
TALENT
The First Affiliated Hospital with Nanjing Medical University
SAIB
First Affiliated Hospital of Zhejiang University
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
RenJi Hospital
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Shanghai Changzheng Hospital
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Peking University People's Hospital
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA
TAS-102 and Anlotinib in ā„3 Lines mGC
Zhejiang University
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
ALTER-G-001
Ruijin Hospital
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
FAITH
Shanghai Zhongshan Hospital
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Nanfang Hospital, Southern Medical University
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Peking Union Medical College Hospital
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
Peking University
ICTCPTLAGC
Xijing Hospital
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Anlotinib Retrospective Study for Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
ALTER-C003
Peking Union Medical College Hospital
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Anlotinib for Esophageal Cancer (AFEC)
Anyang Tumor Hospital
AFHC
People's Hospital of Guangxi Zhuang Autonomous Region
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
Peking Union Medical College Hospital
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Chinese PLA General Hospital
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ALTER-H-002
Shanghai Zhongshan Hospital
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
Zhejiang Cancer Hospital
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Beijing Ditan Hospital
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Zhejiang Cancer Hospital